Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00442936 |
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to an approved medication for acute migraine.
Condition | Intervention | Phase |
---|---|---|
Migraine |
Drug: MK0974 / Duration of Treatment: 1 Day Drug: Comparator: zolmitriptan / Duration of Treatment: 1 Day Drug: Comparator: placebo (unspecified) / Duration of Treatment: 1 Day |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura |
Estimated Enrollment: | 1800 |
Study Start Date: | March 2007 |
Study Completion Date: | October 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2006_525 |
Study First Received: | February 28, 2007 |
Last Updated: | October 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00442936 |
Health Authority: | United States: Food and Drug Administration |
Zolmitriptan Migraine Disorders Headache Central Nervous System Diseases |
Headache Disorders, Primary Brain Diseases Serotonin Headache Disorders |
Serotonin Agonists Neurotransmitter Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action |
Physiological Effects of Drugs Nervous System Diseases Pharmacologic Actions |